TRPC6 and neoplasm: Accordingly, shRNA-mediated TRPC6 inhibition increases tumour responsiveness to doxorubicin treatment, as shown by a five-fold tumour size reduction in the in vivo HCC xenograft compared to doxorubicin-only treatment [35].